Metastatic Hepatocellular Carcinoma on Single Agent Sorafenib: A Case Report

Mohamed Shanshal, Rami Haddad, Rami Y Haddad, Mark F Conneely


Despite the fact that hepatocellular carcinoma is the most common tumor in males worldwide, with approximately 1 million new cases reported annually, no effective systemic therapy exists for patients with advanced disease. Sorafenib which is a multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf, Which was proven in 2007 for the treatment of advanced hepatocellular carcinoma. We report a case of a patient who responded completely and remain disease free for the last 3 years by using a single agent sorafenib. The clinical, radiologic, pathologic and treatment features of this entity are discussed.


Sorafenib; Hepatocellular carcinoma

Full Text: PDF HTML


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.